Articles for author: Ron Finklestien

March 26, 2024

Ron Finklestien

Unleashing the Unstoppable GSK (GSK) Stock: An Investor’s Guide

Moving and Shaking: An Overview GSK (GSK) closed its most recent trading session at $42.79, a slight dip of -0.09%. A meager setback compared to the S&P 500’s loss of 0.28%, the Dow’s drop of 0.08%, and Nasdaq’s decline by 0.42%. Over the past month, GSK has seen its stock rise by 1.16%, outperforming the Medical sector’s loss of 1.21% but lagging behind the S&P 500’s gain of 2.67%. Forecasting Success: What Lies Ahead The spotlight is on GSK as it gears up for its impending earnings report. Analysts expect an EPS of $0.95, marking a 5.56% increase from the

March 26, 2024

Ron Finklestien

Ryvyl Faces Tough Earnings Season: EPS Falls Short, Revenue Beats Expectations in Q4 2023

Source: iQoncept / Shutterstock Ryvyl (NASDAQ:RVYL) has just disclosed its results for the final quarter of 2023. Ryvyl posted earnings per share of -$1.17, strikingly lower than the anticipated EPS of -40 cents. The company’s revenue stood at $22.25 million. This figure surpassed analyst predictions, beating expectations by 23.61% as the revenue was projected to reach $18.00 million. InvestorPlace Earnings is a novel initiative that harnesses data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills critical insights like earnings per share and revenue, along with a comparison to analyst estimates. These pieces are disseminated without human

March 26, 2024

Ron Finklestien

The AEye Odyssey: LIDR Stock Surpasses EPS Expectations, But Falters in Q4 2023 Revenue Battle

Source: iQoncept / Shutterstock AEye (NASDAQ:LIDR) has recently unveiled their fourth-quarter 2023 financial performance. EPS for AEye stood at -$1.10, notably outperforming analyst projections of -$1.20 per share. The company’s revenue for the quarter reached $69,000, falling short by 31% compared to the estimated $100,000 by analysts. InvestorPlace Earnings brings the power of TradeSmith data to the forefront, automating coverage of quarterly financial reports. By swiftly delivering key insights such as EPS, revenue figures, and performance against analyst forecasts, InvestorPlace Earnings offers readers timely updates. To address any concerns or inaccuracies, contact us at [email protected]. Article printed from InvestorPlace Media,

March 26, 2024

Ron Finklestien

Tuesday Loss for Corn Futures

Impasse Hits Corn Futures on Tuesday Corn Prices Stumble Corn futures took a beating on Tuesday, slipping to their lowest points with a loss exceeding a nickel. The new crop futures plummeted by 6 ¾ cents throughout the day. Corn Planting Update As per Safras and Mercado’s report, Brazil has marked 97.3% of corn planting completion for the second crop by 3/22. This figure is a notable increase from 94.7% at the same juncture last year. In Texas, corn planting progress hit 46% by 3/24, a 12% surge from the previous week, and currently stands 3% above the average. Similarly,

March 26, 2024

Ron Finklestien

Insight into Iridex: Q4 2023 Earnings Analysis Insight into Iridex: Q4 2023 Earnings Analysis

Source: iQoncept / Shutterstock Iridex (NASDAQ:IRIX) recently unveiled its financial results for the final quarter of 2023. Iridex posted earnings per share of -18 cents, falling short of the anticipated -5 cents. The company’s revenue stood at $12.46 million, 16.39% below the projected $14.90 million. InvestorPlace Earnings taps into TradeSmith data to auto-generate coverage on quarterly earnings. It offers insights like EPS, revenue, and performance relative to analyst predictions. These reports ensure prompt updates for our audience. For any feedback or discrepancies, reach out to [email protected]. Article printed from InvestorPlace Media, https://investorplace.com/earning-results/2024/03/irix-stock-earnings-iridex-for-q4-of-2023/. ©2024 InvestorPlace Media, LLC

March 26, 2024

Ron Finklestien

Dissecting the Q4 2023 Performance of Aptose Biosciences: A Deeper Look into Earnings Per Share

Source: iQoncept / Shutterstock Aptose Biosciences (NASDAQ:APTO) reveals its latest numbers for the closing quarter of 2023. Aptose Biosciences discloses earnings per share of -$1.44, a figure that surpasses the forecasted EPS of -$1.59. For the quarter in question, the company registers no revenue reported. InvestorPlace Earnings offers a meticulous breakdown using data from TradeSmith to mechanize its coverage of quarterly earnings results. By assessing critical aspects like earnings per share, revenue, and juxtaposing a company’s performance against analyst projections, InvestorPlace Earnings ensures prompt dissemination of information to our audience. These write-ups are generated autonomously, guaranteeing timely updates. Any discrepancies

March 26, 2024

Ron Finklestien

Cattle Drop with Tuesday Follow Through

Cattle Market Plummets Amidst Tuesday’s Stumble A Market in Disarray Yesterday was undoubtedly a dark day for the cattle market, with fat cattle futures facing a significant drop of $3.10 to $3.55 across the front months. The June contract even found itself grappling against the 100-day moving average, hitting the weakest mark since late January. In parallel misery, feeder prices tumbled by as much as 2.13% in the same period, registering losses of $5. The USDA’s lack of cash activity only added to the gloom, with last week’s trade hovering around $188 in the South and nearly $190 in the

March 26, 2024

Ron Finklestien

Direct Digital Holdings Q4 2023 Report: Falling Short of Expectations

Source: iQoncept / Shutterstock Direct Digital Holdings from the NASDAQ exchange under the stock symbol DRCT has recently unveiled their performance charts for the final quarter of 2023. Dishearteningly, their reported earnings per share stood at a dismal -8 cents, a stark contrast to the anticipated 26 cents as per analyst forecasts. Further exacerbating the situation, the company’s revenue rang in at $41.01 million, a substantial 37.81% beneath the predicted $65.95 million revenue mark. InvestorPlace Earnings has introduced a groundbreaking endeavor utilizing TradeSmith data to automate its quarterly earning review. This innovative project meticulously summarizes crucial elements like earnings per

March 26, 2024

Ron Finklestien

Exploring nCino’s (NCNO) Q4 2024 Financial Results nCino Excels in Q4 2024 Earnings Despite Challenging Year

Image source: The Motley Fool. nCino (NASDAQ: NCNO)Q4 2024 Earnings CallMar 26, 2024, 4:30 p.m. ET Highlights: Prepared Remarks Questions and Answers Call Participants Leading the Way: Prepared Remarks Operator Good day, ladies and gentlemen, and welcome to the nCino fourth-quarter and fiscal year 2024 financial results conference call. At this time, all participants are listen only mode. After the speakers’ prepared remarks, there will be a question-and-answer session. [Operator instructions] As a reminder, this conference is being recorded. I would like to turn the call over to Harrison Masters, director, investor relations. Please go ahead. Harrison Masters — Director,

March 26, 2024

Ron Finklestien

Bean Market Pulse: Pricing Pulls Back to $12 Threshold

Overview of Market Movement Tuesday saw the likes of July ’24, Aug ’24, and Jan ’25 contracts struggle to maintain the $12 threshold after experiencing losses ranging from 7 to 10 ¼ cents. Their counterparts in other front months fared worse, closing near session lows below the significant round number. Amidst this turbulence, soymeal futures took a hit with losses ranging from $1.60 to $1.90. Front month Soy Oil futures also faltered, ending the day 53 to 60 points lower, just ~5 points above their session low. Insights from Statistical Data StatsCan’s latest data unveiled that Canada’s Feb canola crush